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a b s t r a c t
Pattern recognition receptors, such as retinoic acid-inducible protein I (RIG-I), Toll-like receptors 3 and 7
(TLR3 and 7), and nucleotide-binding oligomerization domain containing protein 2 (NOD2), play
important roles in the recognition of inﬂuenza A virus (IAV), but their role in interferon (IFN) induction
is still unclear, particularly in human lung. We investigated IFN induction by IAV in the A549 cell line as
well as in primary human alveolar epithelial cells (AEC). TLR3/7, NOD2, RIG-I, and IFN expression levels
were measured by qRT-PCR and ELISA in cells infected with IAV PR8. We found that TLR7 and NOD2
were not involved in IFN induction by IAV in these cells. Neither RIG-I nor TLR3 siRNA alone completely
blocked IFN induction. However, double knockdown of RIG-I and TLR3 completely inhibited IFN
induction by inﬂuenza. Thus, signaling through both RIG-I and TLR3 is important for IFN induction by
IAV in human lung AEC.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Inﬂuenza A virus (IAV) continues to pose an important public
health threat globally each year. The virus triggers intra- and
extracellular receptors during infection to elicit an innate immune
response that serves as a ﬁrst line of protection against intrusion
of any infectious pathogens. Induction of interferon (IFN) is a
critical component of the host response to inﬂuenza infection. IFNs
are further divided into type I (mainly IFN-α and β), II (IFN-γ) and
III (IFN-λ) subtypes, based in part on the differential use of unique
receptors through which they mediate signal transduction to
induce anti-viral activity. Rapid production of type I IFN and
recently discovered type III IFN is a central and essential compo-
nent of the anti-viral response (Kotenko et al., 2003; Stetson and
Medzhitov, 2006).
The innate immune receptors, which detect viral infection, are
called pattern recognition receptors (PRRs). Previous studies have
demonstrated that PRRs, such as retinoic acid-inducible protein I
(RIG-I), toll-like receptors 3 and 7 (TLR3 and 7), nucleotide-binding
oligomerization domain containing protein 2 (NOD2), all play impor-
tant roles in the recognition of IAV (Guo et al., 2007; Malathi et al.,
2007; Mibayashi et al., 2007; Sabbah et al., 2009; Thomas et al., 2009).
RIG-I is believed to play an important role in the recognition of, and
response to, IAV in most types of cells. RIG-I is a highly inducible
cytoplasmic RNA helicase that activates antiviral responses to IAV
leading to IFN production. RIG-I associates with and is activated by IAV
ssRNA, which is uncapped and has a 50-triphosphate moiety
(Pichlmair et al., 2006). Stimulation of RIG-I activates speciﬁc signaling
pathways that lead to activation of NF-κB which is crucial for
inﬂammatory cytokine induction, and/or IRF3/7 which are then
translocated into the nucleus where they act as transcription factors
for type I and III IFNs (Fitzgerald et al., 2003; Kotenko et al., 2003).
RIG-I interacts with mitochondrial antiviral signaling protein (MAVS,
also known as IPS-1), followed by the activation of IRF3/7 via TBK1-
and IKKi-dependent phosphorylation. Signaling events regulated by
RIG-I during IAV infection are important in the antiviral IFN response
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2015.03.048
0042-6822/& 2015 Elsevier Inc. All rights reserved.
n Corresponding to: Pulmonary and Critical Care Division, Department of Med-
icine, University of Oklahoma Health Sciences Center, Room 425, RP1, 800 N.
Research Pkwy. Oklahoma City, OK 73104, USA. Fax: þ1 405 271 5440.
E-mail address: jordan-metcalf@ouhsc.edu (J.P. Metcalf).
Virology 482 (2015) 181–188
and for modulation, either directly or indirectly, of proinﬂammatory
cytokine responses. TLR3/7 trigger antiviral responses in a cell type-
speciﬁc manner. In humans, TLR7 expression is conﬁned to plasma-
cytoid dendritic cells (pDC) including those in human lung (Di
Domizio et al., 2009; Lund et al., 2004). Double-stranded RNA (dsRNA)
is produced during viral replication and is recognized by endosomal
TLR3 (Guillot et al., 2005). Le Gofﬁc reported that the sensing of IAV by
TLR3 primarily regulates a proinﬂammatory response, whereas RIG-I
mediates both a type I IFN-dependent antiviral signaling and a proin-
ﬂammatory response in human epithelial cells (Le Gofﬁc et al., 2007).
Epithelial cells are the primary site of viral replication for IAV,
although monocytes/macrophages and other leukocytes can also be
infected (Ronni et al., 1997; Wang et al., 2009). IAV infection of the
lower respiratory tract of lung is associated with very high morbidity
and mortality (Hers, 1966; Hers et al., 1958; Hers and Mulder, 1961).
This can progress to fatal pneumonia (Cox and Subbarao, 1999). The
interactions between host immune responses and IAV determine the
outcome of infection. Alveolar epithelial cells (AEC), located in the
lower respiratory tract, are comprised of two main cell types: type I
and type II AEC. IAV speciﬁc antigen has been found in both types of
AEC, as well as in alveolar macrophages. AEC respond in several ways
to limit viral spreading. The IFN responses are the central component
of innate immune control of viral infection. Once released, type I and
III IFNs bind to their respective receptors on the same and neighbor-
ing cells. Receptor engagement subsequently leads to the activation of
the IFN-stimulated regulatory factor 3 (ISGF3) transcription complex
(Kotenko et al., 2003). The activation of this transcriptional activator
complex leads to the increased expression of interferon-stimulated
genes (ISGs), including 20,50-oligoadenylate synthetase (OAS), Mx
proteins, and protein kinase R (PKR), inducing an antiviral state
(Zhou et al., 1999). PKR, OAS, and MxA have similar roles in their
ability to sense and degrade viral RNAs, and induce apoptosis of the
infected cells (Jewell et al., 2010; Stark et al., 1998).
We have shown that RIG-I is critical for the initiation of the
early antiviral cytokine response in the human lung using a human
lung organ culture model (Wu et al., 2010, 2011, 2012). We have
recently mastered the technique of isolation of highly puriﬁed
human AEC (Langer et al., 2012). In this study, we will use our
highly puriﬁed human AEC, as well as A549 cells, a widely used
in vitro model for human type II alveolar epithelial cells, to
examine the role of PRRs in the important type I and type III IFN
anti-viral responses to IAV.
Results
RIG-I and TLR3, but not TLR7 and NOD2, are induced by IAV infection
in A549 and type II AEC
We isolated and puriﬁed human AEC using standard methods
as previously described (Langer et al., 2012). Isolation of human
AEC is known to result in an initial culture consisting mainly of
surfactant-producing AEC II cells (Fig. 1A), which differentiate into
AEC I phenotype over 8–10 days in culture (Fig. 1B). Our isolated
AEC I-like cells expressed the tight junction component zonula
occludens-1 (ZO-1) (Fig. 1B). Differentiation of AEC II resulted in
detection of the purinergic receptor P2X7, which was previously
shown to be expressed primarily in rat AEC I (Chen et al., 2004).
Flow cytometry data of AEC staining with α-human P2X7 deter-
mined that 73.2% of cells were positive for P2X7 (Fig. 1D). In
subsequent experiments described below, AEC were cultured for
Fig. 1. Isolation and culture of primary human AEC. (A) Culture of isolated AEC cells at 4 days. The cells have AEC II morphology and produce surfactant, as expected.
Bar¼250 μm. (B) AEC II differentiate into AEC I-like cells. At 10 days in culture, cells show an increase in diameter, are conﬂuent in areas, exhibit an AEC I-like morphology,
and stain positive for the tight junction protein ZO-1. A representative ﬁeld is shown with ZO-1 stained using α-human ZO-1 antibody labeled with Alexa Fluor-488 (green)
and DNA stained with DAPI (blue). Bar¼100 μm. (C) AEC II identity is conﬁrmed by differentiation into primary human AEC I-like cells expressing the AEC I purinergic
receptor P2X7. A representative ﬁeld is shown with ZO-1 stained with α-human ZO-1 (green); DNA stained with DAPI (blue); and P2X7 stained with α-human purinergic
receptor P2X7 antibody labeled with Alexa Fluor-555 (red). (D) Representative ﬂow cytometry histogram of AEC staining with α-human P2X7 determined that 73.2% of cells
were positive for P2X7. Blue line, P2X7-FITC labeled cells; Red line, isotype control labeled cells. Bar¼100 μm.
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approximately four days before viral infection in order to study the
effects of IFN response to IAV in a primarily type II AEC phenotype.
To determine which PRRs are essential for the IFN response in
human lung alveolar epithelia, A549 cells were infected by IAV PR8
at the MOI of 1. Viral diluent (PBS) was used for mock infection.
After 24 h, RIG-I, TLR3, TLR7 and NOD2 mRNA induction in
collected cells were assessed by qRT-PCR. PR8 infection of A549
cells (Fig. 2A) caused a 49 and 13 fold increase above mock-
infected cells for RIG-I and TLR3 mRNA, respectively. There was
minimum mRNA induction for TLR7 and NOD2. As A549 cells were
originally derived from an alveolar adenocarcinoma, it cannot be
excluded that they respond differently to external stimuli than
primary cells. Therefore, to put our results with A549 cells into
perspective, we repeated the experiments with our isolated
primary human type II AEC. Similar to A549 cells, PR8 infection
of AEC (Fig. 2B) caused a 27 and 12 fold increase above mock-
infected cells for RIG-I and TLR3 mRNA, respectively. TLR7 and
NOD2 were not induced by IAV in these cells. A dose response
curve using different MOI of PR8 on A549 cells demonstrated that
RIG-I and TLR3 mRNA induction was increased when higher IAV
amounts were added to the cells, but TLR7 and NOD2 induction
did not occur at any IAV dose (Fig. 2C, and TLR7, NOD2 not shown).
These experiments suggest that RIG-I and TLR3 gene expression is
likely necessary for the cytokine response to IAV PR8 in human
AEC, while TLR7 and NOD2 are not involved in the response in
human lung alveolar epithelia.
Type III IFNs are the major antiviral cytokines induced by IAV
infection in A549 and type II AEC
In order to determine the major IFN induced by IAV, IFN sub-
type and antiviral cytokine IP-10 gene expression was assessed in
PR8 infected A549 cells. Although IFN-β mRNA was signiﬁcantly
induced by the virus, 27 fold over mock, IFN-λ1 and IFN-λ2/3 were
induced to a much greater degree at 375 and 587 fold over mock,
respectively (Fig. 3A). Again, we repeated the experiments with
primary human type II AEC. PR8 infection induced IFN-β mRNA
7 fold over mock. However, IFN-λ1and IFN-λ2/3 induction was
more signiﬁcant, and had a 63 and 27 fold increase over mock,
respectively (Fig. 3B). In the same experiment, IP-10 mRNA
induction in A549 and primary AEC was 45 and 18 fold increase
over mock, respectively.
To conﬁrm the result, we determined the IFN protein level in
the supernatant of cultured cells. We were not able to detect any
IFN-β protein in the supernatants using ELISA. Since the detection
range of the ELISA is between 60 and 4000 pg/ml, the concentra-
tion of IFN-β is below 60 pg/ml in the supernatants. IFN-λ2/3
protein was signiﬁcantly increased in the supernatants at 190 and
290 pg/ml from A549 and AEC, respectively (Fig. 4A). The other
important antiviral cytokine IP-10 was also detected in the super-
natant at 163 and 142 pg/ml in A549 and AEC, respectively
Fig. 2. RIG-I and TLR3, but not TLR7 and NOD2, are induced by inﬂuenza virus
infection in A549 (A), type II AEC (B), and (C) PR8 Dose Response. After infection of
A549 or AEC cells with IAV PR8 at an MOI of 1 for 24 h (A and B), total RNA was
extracted and cell PRR mRNA expression was assessed by qRT-PCR. (C) A549 cells
were infected by PR8 at increasing MOIs. Transcript levels of PRR were normalized
relative to the constitutively expressed β-actin gene. Data were expressed as the
means7SEM from three separate experiments. Statistical signiﬁcance was deter-
mined by ANOVA. *denotes signiﬁcant difference compared to data from the mock
treated group, Po0.05.
Fig. 3. Type III IFNs are the major antiviral cytokines induced by inﬂuenza virus
infection in A549 (A) and type II AEC (B). After infection of A549 or AEC cells with
inﬂuenza virus PR8 at the MOI of 1 for 24 h, total RNA was extracted and cell
cytokine mRNA expression was assessed by qRT-PCR. Transcript levels of the
cytokines were normalized relative to the constitutively expressed β-actin gene.
Data were expressed as the means7SEM from three separate experiments.
Statistical signiﬁcance was determined by ANOVA. * denotes signiﬁcant difference
compared to data from the mock treated group, Po0.05. # denotes signiﬁcant
difference between the indicated groups, Po0.05.
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(Fig. 4B). In terms of the interferon response to IAV infection, these
results demonstrate that type III IFN- λ responses are more promi-
nent than type I IFN responses in human AEC.
Both RIG-I and TLR3 are required for IFN mRNA induction by IAV in
human lung epithelial cells
In order to speciﬁcally silence RIG-I and TLR3 mRNA production
in previously transfected A549 cells, we made use of siRIG-I and
siTLR3 to knock down gene expression of these PRRs. First, we
tested the inhibition efﬁciency of siRNA against RIG-I and TLR3.
RIG-I and TLR3 mRNA induction by PR8 was blocked 89% and
85%, respectively, in the corresponding siRNA treated cells (Fig. 5A
and B). We also conﬁrmed RIG-I protein knockdown using western
blot in the siRIG-I treated cells (Fig. 5C).
With regards to the role of speciﬁc PRR activation in cytokine
induction, IFN-β mRNA induction was decreased only 55% in RIG-I
siRNA treated cells compared to control siRNA treated cells (Fig. 6A).
Surprisingly, IFN-βmRNA induction in TLR3 siRNA treated cells only
showed 14% decrease compared to control siRNA treated cells.
Similarly, IFN-λ1 mRNA induction in RIG-I and TLR3 single
siRNA treated cells was decreased 75% and 41%, respectively,
compared to control siRNA treated cells (Fig. 6B). Thus, single
siRNA treatment of the cells did not completely block IFN produc-
tion. However, double knockdown of RIG-I and TLR3 almost
completely blocked the IFN induction by IAV, with 93% and 88%
reduction of IFN-λ1 and IFN-β mRNA induction, respectively.
Regarding IFN-λ2/3, IFN-λ2/3 mRNA induction by PR8 appeared
to be inhibited to a greater degree by double knockdown of RIG-I
and TLR3 than by single knockdown of either PRR although the
difference did not reach statistical signiﬁcance (Fig.6C). The results
suggested that either RIG-I or TLR3 initiated IFN mRNA induction
during IAV infection. For maximum induction of IFN, both RIG-I
and TLR3 were required to be activated.
We conﬁrmed the IFN-λ1 and 2/3 induction at level of transla-
tion using ELISA. The protein levels for the most part reﬂected
mRNA expression with a few differences. For instance, IFN-λ1
protein in the supernatant was not inhibited by TLR3 siRNA,
suggesting there may be a role for posttranscriptional regulation
of IFN-λ1 by TLR3. However, IFN-λ protein induction by IAV also
required both RIG-I and TLR3 activation, as knockdown of both
PRRs further inhibited IFN-λ (Fig. 7).
Both RIG-I and TLR3 contribute to activation of interferon regulatory
factor 3 (IRF3) during IAV infection of human lung epithelial cells
Inﬂuenza virus-activated RIG-I binds to its adapter, MAVS, and
activates speciﬁc signaling pathways that lead to phosphorylation
of interferon regulatory factor 3 (IRF3) and subsequent production
of type I and III IFN. The phosphorylated IRF3 (phospho-IRF3) then
homodimerizes and enters the nucleus to activate IFN in a highly
cooperative manner with NF-κB (Seth et al., 2005; Wu et al., 2011).
Thus, IRF3 is a major regulator of IFN production at the level of
transcription. We examined phospho-IRF3 and total IRF3 protein
Fig. 4. IFN-λ 2/3 (A) and IP-10 (B) are the major antiviral cytokines detected in the
supernatant of inﬂuenza virus infected A549 and type II AEC. After infection of
A549 or AEC cells with inﬂuenza virus PR8 at the MOI of 1 for 24 h, supernatants
were collected and cytokine expression was assessed by ELISA. Data were
expressed as the means7SEM from three separate experiments. Statistical sig-
niﬁcance was determined by ANOVA. * denotes signiﬁcant difference compared to
data from the mock treated group, Po0.05.
Fig. 5. Speciﬁc siRNA knocked down inﬂuenza-mediated RIG-I (A) and TLR3 mRNA
(B) induction. A549 cells were ﬁrst transfected with RIG-I or TLR3 siRNA for three
days and then infected with inﬂuenza virus PR8 at a MOI of 1 for 24 h. Total RNA
was extracted and mRNA expression was assessed by qRT-PCR. Transcript levels of
mRNA were normalized relative to the constitutively expressed β-actin gene.
(C) RIG-I protein in cells was detected by immunoblotting, normalized to GAPDH.
Data were expressed as the means7SEM from three separate experiments.
Statistical signiﬁcance was determined by ANOVA. * denotes signiﬁcant difference
compared to data from the mock treated group, Po0.05.
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levels by immunoblotting in siRNA treated IAV infected A549 cells.
Phosphorylation of IRF3 occurred after IAV PR8 infection in control
siRNA treated cells. The amount of phospho-IRF3 was reduced by
RIG-I and TLR3 single siRNA treatment. However, maximal inhibi-
tion of IRF3 phosphorylation occurred only when RIG-I and TLR3
double knockdown was performed (Fig. 8). Thus, induction of the
downstream pathway leading to IFN production involves both
RIG-I and TLR3.
Discussion
Interaction of IAV with the innate immune system involves the
induction of multiple PRR pathways triggered simultaneously by
various pathogen-associated molecular patterns (PAMP) and dif-
ferent life cycles of the virus. RIG-I is identiﬁed as the central
regulator of IAV-induced expression of antiviral cytokines in
human lung epithelial cells (Matikainen et al., 2006). TLR3, in
contrast, triggers proinﬂammatory cytokines in response to IAV in
epithelial cells (Le Gofﬁc et al., 2007). The detrimental contribu-
tion of TLR3 is supported by an animal experiment showing that
TLR3-deﬁcient mice survive longer than wild-type mice following
lethal IAV infection likely due to TLR3 induction of uncontrolled
inﬂammation (Le Gofﬁc et al., 2006). It is known that TLR3 is
highly expressed in mouse innate immune cells, but has a low
level of expression in human monocytes, macrophages and den-
dritic cells (DC) (Heinz et al., 2003). This may be responsible for
conﬂicting results demonstrated in studies examining the role of
TLR3 in the innate immune response using human and mouse
models. Here, we have demonstrated that RIG-I and TLR3 are the
two major PRRs induced by IAV infection in human A549 and type
II AEC. Single knockdown of either RIG-I or TLR3 does not
completely abolish IFN induction. Similarly, Slater and colleagues
also found that inhibition of TLR3 and RIG-I by siRNA reduced IFN
induction using rhinovirus infected human primary bronchial
Fig. 6. Both RIG-I and TLR3 are required for IFN mRNA induction by inﬂuenza virus
in human lung epithelial cells. A549 cells were ﬁrst transfected with RIG-I or TLR3
siRNA for three days and then infected with inﬂuenza virus PR8 at the MOI of 1 for
24 h. Total RNA was extracted and mRNA expression was assessed by qRT-PCR.
Transcript levels of mRNA were normalized relative to the constitutively expressed
β-actin gene. Data were expressed as the means7SEM from three separate
experiments. Statistical signiﬁcance was determined by ANOVA. * denotes sig-
niﬁcant difference compared to data from the mock treated group, Po0.05.
# denotes signiﬁcant difference between the indicated groups, Po0.05.
Fig. 7. Both RIG-I and TLR3 are required for IFN-λ1 (A) and 2/3 (B) protein induction
by inﬂuenza virus in human lung epithelial cells. A549 cells were ﬁrst transfected
with RIG-I or TLR3 siRNA for three days and then infected with inﬂuenza virus PR8 at
an MOI of 1 for 24 h. Supernatants were collected and cytokine expression was
assessed by ELISA. Data were expressed as the means7SEM from three separate
experiments. Statistical signiﬁcance was determined by ANOVA.
Fig. 8. Both RIG-I and TLR3 contribute to activation of interferon regulatory factor 3
(IRF3) during IAV infection in human lung epithelial cells. A549 cells were ﬁrst
transfected with RIG-I or TLR3 siRNA for three days and then infected with
inﬂuenza virus PR8 at a MOI of 1 for 24 h. IRF3 phosphorylation in cells was
detected by immunoblotting, normalized to GAPDH.
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epithelial cells (Slater et al., 2010). Our data differs in that we did
not ﬁnd that TLR3 induces RIG-I gene and protein expression. The
data suggest that the possible interaction of RIG-I or TLR3 signal-
ing pathways against IAV might be potentiating (synergistic),
instead of weakening (hampering), in human AEC. Either of them
may function as a backup for antiviral immunity when the other
signaling mechanism is shut down. Single knockdown of TLR3 did
not have as strong an effect on IFN induction as knockdown of
RIG-I. There are two possibilities. First, TLR3 may play a lesser role
in sensing ﬂu as RIG-I. Alternately, RIG-I silencing overall may be
more efﬁcient than TLR3 silencing although this was not reﬂected
at the level of transcription in the RIG-I and TLR3 mRNA assays.
All type I IFNs bind to a speciﬁc cell surface receptor complex
known as the IFN-α receptor (IFNAR). Type III IFNs signal through
a heterodimeric cell surface receptor composed of two chains:
IFNLR1 and IL10R2 (Kotenko et al., 2003; Sheppard et al., 2003).
The IFNAR complex is present on most if not all nucleated cells,
whereas expression of the IFNLR1 subunit seems to be restricted
to cells of epithelial origin (Brand et al., 2005). Consequently,
antiviral protection by type I IFN is observed in most cell types,
whereas antiviral protection mediated by type III IFN is restricted
to cells that express functional IFNLR1/IL10R2 complexes. Recent
experiments suggest that epithelial cells are the main targets of
type III IFN in the mouse (Sommereyns et al., 2008). An important
issue to be addressed currently is whether type III IFN might serve
a similar role in human epithelial cells as in mice. When type I and
type III IFN receptors are expressed by a single cell line, triggering
either receptor complex leads to the upregulation of the same set
of ISGs (Zhou et al., 2007). Therefore, a major question is which
types of IFNs are more redundantly produced in humans. In this
report, we demonstrate that type III IFNs (IFN λ1 and λ2/3) are the
major antiviral cytokines induced by IAV infection in human AEC.
Combined with earlier reports from other investigators, type III
IFNs are likely the principal IFNs produced during innate
responses to RNA viruses in human respiratory epithelia (Khaitov
et al., 2009; Wang et al., 2009). The results suggest that human
AEC might play a vitally important role in detection (through RIG-I
and TLR3) and elimination (through type III IFN) of IAV.
Taken together, we have found that IAV-induced antiviral IFN
responses require both RIG-I and TLR3 induction in human lung
epithelia. TLR3 and RIG-I cooperate in mediating innate antiviral
IFN responses in human AEC cells, which may contribute to the
defense of the lung against viral infections. More work is needed
in the future to address whether RIG-I and TLR3 compensation
plays a role in inﬂuenza infection.
Materials and methods
Cell culture
The human pulmonary epithelial cell line, A549, was obtained
from the American Type Culture Collection (ATCC, Manassas, Va.,
CCL-185). The A549 cell line has the characteristics of alveolar type
II cells. A549 cells were propagated in Dulbecco0s modiﬁed Eagle
Medium (DMEM) containing 10% fetal bovine serum (FBS), 2 mM
L-glutamine, and 80 mg of gentamicin/ml.
Isolation of primary pneumocytes
One lobe of human lung obtained from the National Disease
Research Interchange (NDRI, Philadelphia, PA) or the International
Institute for the Advancement of Medicine (IIAM, Jessup, PA) under a
protocol approved by the University of Oklahoma Health Sciences
institutional review board, was perfused with 2 L Plasma-Lyte A
Injection (Baxter Healthcare Corp., Deerﬁeld, IL) followed by lavage
with 2 L physiological saline containing 100 mg/ml of crude DNase
from bovine pancreas (Sigma-Aldrich Co., St. Louis, MO). Approxi-
mately 55 g of tissue were injected with a digestion solution
comprised of 8 U/ml porcine elastase (Wothington Biochemical Corp,
Lakewood, NJ) and 150 KU/ml DNase in 150 ml Hanks Balanced Salt
Solution (HBSS) without Ca2þ , Mg2þ or phenol red (Mediatech, Inc.,
Manassas, VA). After incubation at 37 1C for 60 min in a shaking
water bath, the enzyme was inactivated by addition of 48 ml
HyClone FBS (Thermo Fisher Scientiﬁc, Inc., Waltham, MA) plus
200 mg DNase. The softened tissue was cut into ﬁne bits, and the
slurry was passed sequentially through 1-ply gauze, 2-ply gauze,
150 mm mesh (Small Parts, Inc., Logansport, IN), and 30 mm mesh.
Following concentration into 40 ml plain DMEM, 150 mg/ml DNase,
cells were panned for 60 min at 37 1C in 2T-175 ﬂasks previously
coated with 20 mg/cm2 human IgG. Unattached cells were pelleted
and resuspended in DMEM/DNase solution, and 2 ml were overlayed
into each of 430 ml Corex tubes, all containing 11 ml of Percoll
solution ρ¼1.040 layered over 11 ml ρ¼1.089 (GE Healthcare
Biosciences, Piscataway, NJ). The gradient was formed by centrifuga-
tion at 400 g for 20 min, 16 1C, without braking. The predominant
band was negatively selected against CD45þ Dynabeads (Invitrogen
Corp., Carlsbad, CA) for 40 min at 4 1C. Average yield was 5.7107
live, single cells with 91% viability.
All cells were grown in AEC media consisting of DMEM, 10%
Hyclone FBS, 1% pen/strep/Amphotericin B (Mediatech, Inc., Man-
assas, VA), 0.5 mg/100 ml vancomycin, and 1.0 mg/100 ml ceftazi-
dime (both from Sigma-Aldrich Co., St. Louis, MO). Media was
changed every 2 days. Freshly cultured cells were used for all
experiments because freezing, storage and thawing led to low
recovery of viable cells.
Preparation of inﬂuenza virus stock
H1N1 inﬂuenza virus, A/PR/34/8 (PR8), was passaged in
Madin–Darby canine kidney (MDCK) cells. Virus was grown in
MDCK cells in DMEM/F12 with ITSþ (BD Biosciences, Franklin
Lakes, NJ) and trypsin, harvested at 72 h postinfection and titered
by plaque assay in MDCK cells. There was no detectable endotoxin
in the ﬁnal viral preparations used in the experiments as deter-
mined by limulus amebocyte lysate assay (Cambrex, Walkersville,
MD). The lower limit of detection of this assay is 0.1 EU/ml or
approximately 20 pg/ml LPS.
siRNA transfection into A549 cells
For siRNAs treatment, A549 cells were plated 24 h before
treating with siRNAs (100 nM; Ambion). siRNA was diluted in
250 ml of Opti-MEM medium and mixed gently. 5 ml of Lipofecta-
mine 2000 (Invitrogen) were added in 250 ml Opti-MEM medium
and incubated for 5 min. Diluted siRNA and Lipofectamine 2000
were combined and mixed gently and incubated for 20 min at RT.
The siRNA-Lipofectamine 2000 complexes were added to each well
and mixed gently. siRNA ﬁnal concentration was 100 nM. The cells
were incubated at 37 1C for 24 h. On-target plus siRNA to human
RIG-I was from Thermo Scientiﬁc Dharmacon (Cat#J-012511-08).
TLR3 silencer select siRNA was from Ambion (Cat#4390824).
Measurement of mRNA expression by quantitative real-time PCR
(qRT-PCR)
Total RNA from cells was extracted using a modiﬁed TRIzol
(Invitrogen, Carlsbad, CA) protocol, spectrophometrically quantitated,
and the integrity veriﬁed by formaldehyde agarose gel electrophor-
esis. Equal amounts (1 mg) of RNA from each sample were used with
oligo (dT) as primers for production of cDNA (SuperScript II First-
Strand Synthesis System for RT-PCR, Invitrogen, Carlsbad, CA). Gene
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speciﬁc primers for the PRRs, cytokines and the β-actin house-
keeping genes were used. qRT-PCR was performed using 100 ng
sample RNA and SYBR Green (Quanta Biosciences, Gaithersburg, MD)
in a Bio-Rad CFX96™ Touch Real-Time PCR Detection System. Results
were calculated and graphed from the ΔCT of the target gene and
normalizer. The primers' sequences were as follows: RIG-I forward
50-TCCTTTATGAGTATGTGGGCA-30; RIG-I reverse 50-TCGGGCACAGAA-
TATCTTTG-30; IFN-β forward 50-GCTCTCCTGTTGTGCTTCTCCAC-30;
IFN-β reverse 50-CAATAGTCTCATTCCAGCCAGTGC-30; β-actin forward
50-GCCAACCGCGAGAAGATGACC-30; β-actin reverse 50-CTCCTTAATG-
TCACGCACGATTTC-30; TLR3 forward 50–GTCTGGGAACATTTCTCTTC-
30; TLR3 reverse 50–GATTTAAACATTCCTCTTCGC-30; NOD2 forward
50–GAAGTACATCCGCACCGAG-30; NOD2 reverse 50-GACACCATCCAT-
GAGAAGACAG-30; TLR7 forward 50-TGGAAATTGCCCTCGTTGTT -30;
TLR7 reverse 50-GTCAGCGCATCAAAAGCATT-30; IFN-λ1 forward 50-
CGCCTTGGAAGAGTCACTCA-30; IFN-λ1 reverse 50-GAAGCCTCAGGTC-
CCAATTC-30; IFN-λ2/3 forward 50-AGTTCCGGGCCTGTATCCAG-30;
IFN-λ2/3 reverse 50-GAGCCGGTACAGCCAATGGT-30; IP-10 forward
50–TCTAGAACCGTACGCTGTACCTGC-30; IP-10 reverse 50-CTGGTTTTA-
AGGAGATCT-30.
ELISA and multiplex immunoassay
ELISAs of IP-10 and IFN-β, λ1, λ2/3 cytokine protein levels in the
supernatants were all performed using commercially available kits
(R&D system, Minneapolis, MN).
RIG-I and IRF3 protein determination by immunoblotting
The cells were harvested and homogenized, and then lysed in
500 ml of cold lysis buffer (150 mM NaCl, 50 mM Tris,pH 8.0,
10 mM EDTA, NaF, sodium pyrophosphate, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 10 mg of leupeptin/ml). Cell homogenates
were clariﬁed by centrifugation at 10,000 g, at 4 1C for 10 min,
and the clariﬁed lysates were mixed with SDS-PAGE sample buffer
(60 mM Tris,pH 6.8, 10% glycerol, 2.3% SDS) and heated to 95 1C for
5 min. The samples were separated by 4–15% gradient gel and
electrophoretically transferred to polyvinylidene ﬂuoride (PVDF)
membranes. For the detection of proteins, the membranes were
immunoblotted with rabbit polyclonal antibody speciﬁc for RIG-I,
phospho-IRF3, total IRF3 (Abcam, Cambridge, MA) and GAPDH
(R&D Systems). The membranes were viewed with horseradish
peroxidase-labeled goat anti-rabbit IgG (Cell Signaling Technology,
Beverly, MA) and chemiluminescent reagents (Pierce Biotechnol-
ogy, Rockford, IL). Blots were developed using the Syngene G:box
Bioimaging System and GeneTools software (Syngene, Frederick,
MD) and quantiﬁed using ImageQuant software (BD/Molecular
Dynamics, Bedford, MA).
Statistical analysis
Where applicable, the data have been expressed as the mean-
s7standard error of the mean (SEM). Statistical signiﬁcance was
determined by one-way ANOVA with Student-Newman-Keuls
post-hoc correction for multiple comparisons. Signiﬁcance was
considered as Po0.05.
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